Immune Checkpoint Proteins
Immune blockade therapy has been becoming a new weapon in fighting cancer due to the development of immune checkpoint proteins targeting in cancer, especially after the success of antibody drugs targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).
Although immune checkpoint blockade therapy often leads to more durable response than chemo or targeted therapies in some cases, clinical data shows its bottleneck that in most cancers, the response rate is low (10-30%). Therefore, more associated studies focus on the mechanisms of non-responsiveness, as well as finding new targeting strategies using other immune checkpoint proteins.
Based on our featured SAMSTM platform, Kactus has developed a series of immune checkpoint proteins with multiple pre-labels.